Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Nov 01, 2022 11:28am
146 Views
Post# 35063209

RE:RE:RE:Official termination of distribution rights in Europe

RE:RE:RE:Official termination of distribution rights in Europe TH did not put out any press release about this today. Taimed announced it as they likely had to from a regulatory standpoint. But it shows up on Bloomberg as a headline for TH when you pull up a quote on THTX because TH is mentioned in Taimed's release about it. Despite that, the algo's do not seem to be paying attention to it. I would love to know what the final tally was on dollars TH put into Europe for Trogarzo versus the dollars they got out of the exercise. Actually, maybe I would rather not know at this point. I beleive it was just about a year ago Paul was telling us everything was looking good in the pricing negotiations but Taimed's notice today indicated they could not obtain a price that made it profitable for them.

qwerty22 wrote:

"Taimed Biologics Says"

Nothing to do with them.

 

Biobob wrote: I understand this formalizes an old news I guess but my first impression is... Why put this out for the algorithms to pickup and make more damage at this point in time.  What does this news bring to the table apsrt from a negative headline and additional frustration for shareholders.  It's a non event but still a negative headline to put out.  But maybe they have to because it's Taimed.  

 

 



<< Previous
Bullboard Posts
Next >>